MorphImmune – Could Cellular Reprogramming Be the Next Innovation in Cancer and Fibrosis?
Ronald Martell, President and CEO at MorphImmune discusses MorphImmune’s proprietary platform that enables reprogramming or removal of aberrant cells with targeted effector molecules linked to precision small molecules and is further designed to enable the creation of countless combinations of targeted molecules to treat a wide variety of diseases effectively and safely. The company’s discovery platform has enabled the identification of 10+ additional targets for consideration.
Frequently Asked Questions
What is the main topic discussed in this episode of Health Professional Radio?
This episode covers important developments in healthcare, including updates on Cancer. Health Professional Radio brings you expert insights and analysis on the latest medical news affecting healthcare professionals and patients alike.
How can healthcare professionals benefit from this information?
Healthcare professionals can stay informed about the latest developments in Cancer and related fields, enabling them to provide better patient care. Staying current with medical news helps clinicians make evidence-based decisions in their practice.
Where can I find more information about Cancer?
For more detailed information, listen to the full episode on Health Professional Radio and visit hpr.fm for additional resources. You can also subscribe to our podcast for regular updates on healthcare news and expert interviews.
Ronald Martell, President & CEO, MorphImmune.
A serial entrepreneur, Ronald Martell has founded five biopharmaceutical companies and served on the boards of directors of several others. Prior to joining MorphImmune, Inc., Martell served as the President and CEO of Nuvelution Pharma. He was also Co-Founder and Executive Chairman of Indapta, Orca Bio and Co-Founder and CEO of Achieve Life Sciences, where he led the merger of the company with Oncogenex. Martell has served as the CEO of three public biopharmaceutical companies, including Sevion and NeurogesX, and has overseen billions of dollars in industry transactions. Earlier in his career, Martell served as Senior Vice President of Commercial Operations at ImClone Systems, where he was instrumental in deals with Bristol-Myers Squibb and Merck KGaA, and built ImClone Systems’ worldwide operations to market and commercialize Erbitux ®. He also served in various leadership positions with Genentech where, as Group Manager, Oncology, he was responsible for building the company’s oncology franchise, including the launch of Herceptin ® and Rituxan ®.
Medical Disclaimer
The information provided on this website is for general informational purposes only and is not intended as medical advice. Always consult with a qualified healthcare professional for medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
